信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01801 信达生物

休市中 05-03 16:09:00

40.900

-0.950

-2.27%

最高42.550	最低39.950	成交量741.32万
今开42.000	昨收41.850	日振幅6.21%
总市值663.68亿	流通市值663.68亿	总股本16.23亿
成交额3.04亿	换手率0.46%	流通股本16.23亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"信达生物","latestPrice":40.9,"timestamp":1714723740028,"preClose":41.85,"halted":0,"volume":7413177,"delay":0,"floatShares":1622682897,"shares":1622682897,"eps":-0.7174109,"marketStatus":"休市中","marketStatusCode":7,"change":-0.95,"latestTime":"05-03 16:09:00","open":42,"high":42.55,"low":39.95,"amount":304229811,"amplitude":0.062127,"askPrice":40.9,"askSize":12500,"bidPrice":40.85,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":-0.7184221381918187,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714959000000},"adr":0,"listingDate":1540915200000,"adjPreClose":41.85,"openAndCloseTimeList":[[1714699800000,1714708800000],[1714712400000,1714723200000]],"volumeRatio":0.913205088561974,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK"},"requestUrl":"/m/hq/s/01801/tweets","defaultTab":"tweets","newsList":[{"id":"2432909624","title":"信达生物(01801)授出3371份购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2432909624","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2432909624?lang=zh_cn&edition=full","pubTime":"2024-05-03 22:42","pubTimestamp":1714747349,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信达生物(01801)发布公告，于2024年5月3日，公司根据首次公开发售后雇员持股计划的条款向独立非执行董事陈先生授出3371份购股权，惟须待陈先生接纳。所授出购股权的行使价为每股股份40.90港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1117176.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432282909","title":"信达生物(01801.HK)授出3371份购股权及9551股受限制股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2432282909","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2432282909?lang=zh_cn&edition=full","pubTime":"2024-05-03 22:40","pubTimestamp":1714747242,"startTime":"0","endTime":"0","summary":"格隆汇5月3日丨信达生物(01801.HK)公告，于2024年5月3日，公司根据首次公开发售后雇员持股计划的条款向独立非执行董事陈树云授出3371份购股权，惟须待陈接纳。董事会宣布，于2024年5月3日，公司根据2020年受限制股份计划向陈树云授出9551股受限制股份，惟须待陈接纳及独立股东于股东周年大会上批准后，方可作实。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405032240548b709d65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405032240548b709d65&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432697906","title":"信达生物(01801)：张倩获委任为执行董事及战略委员会成员","url":"https://stock-news.laohu8.com/highlight/detail?id=2432697906","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2432697906?lang=zh_cn&edition=full","pubTime":"2024-05-03 22:24","pubTimestamp":1714746276,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信达生物(01801)发布公告，自2024年5月3日起，陈树云先生已获委任为独立非执行董事、董事会薪酬委员会、董事会战略委员会及董事会提名委员会各自的成员，而张倩女士已获委任为执行董事及战略委员会成员。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1117172.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432175899","title":"建银国际：维持信达生物(01801)“跑赢大市”评级 目标价上调至54.7港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2432175899","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2432175899?lang=zh_cn&edition=full","pubTime":"2024-05-03 13:39","pubTimestamp":1714714749,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，建银国际发布研究报告称，维持信达生物“跑赢大市”评级，该行认为信达生物是中国医药行业中的首选股之一，目标价由54.3港元上调至54.7港元，有信心公司销售增长更光明。鉴于推动更高产品收入所需的销售成本，该行将信达生物2024至2026年的销售与管理费用预测上调7%、11%与12%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1117049.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432997766","title":"《大行》建银国际微升信达生物(01801.HK)目标价至54.7元  有信心销售增长更光明","url":"https://stock-news.laohu8.com/highlight/detail?id=2432997766","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2432997766?lang=zh_cn&edition=full","pubTime":"2024-05-03 10:34","pubTimestamp":1714703640,"startTime":"0","endTime":"0","summary":"建银国际发表报告指出，信达生物首季总产品收入按年增长超过60%，至逾17亿元人民币，占该行对公司今年总收入预测的24.2%。鉴于推动更高产品收入所需的销售成本，该行将信达生物2024至2026年的销售与管理费用预测上调7%、11%与12%。该行认为信达生物是中国医药行业中的首选股之一，将其目标价由54.3元上调至54.7元，维持“跑赢大市”评级，有信心公司销售增长更光明。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220906114108815_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220906114108815_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1347183/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2432960259","title":"《大行》里昂升信达生物(01801.HK)目标价至58.1元  首季业绩强劲","url":"https://stock-news.laohu8.com/highlight/detail?id=2432960259","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2432960259?lang=zh_cn&edition=full","pubTime":"2024-05-03 09:43","pubTimestamp":1714700580,"startTime":"0","endTime":"0","summary":"里昂发表研究报告指，信达生物(01801.HK) 2024财年首季产品销售额按年增长60%，表现超出预期。加上在近月创新药政策的推动下，该行对公司未来数季的销售前景仍充满信心。里昂因而将信达生物的目标价由57.5元上调至58.1元，维持“买入”评级。(js/cy)(港股报价延迟最少十五分钟。沽空资料截至 2024-05-02 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20181016155302092_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20181016155302092_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1347145/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2432965029","title":"信达生物(01801)出现大手卖出50万股，成交价$42.0，涉资2.1千万","url":"https://stock-news.laohu8.com/highlight/detail?id=2432965029","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2432965029?lang=zh_cn&edition=full","pubTime":"2024-05-03 09:30","pubTimestamp":1714699800,"startTime":"0","endTime":"0","summary":"[大手成交]信达生物(01801)在上午09:30出现大手卖出，成交量为50万，成交价为港币$42.0，涉资2.1千万。至目前为止，股价升1.314%，今日最高价为$42.4，而最低价为$41.0，总成交量为194.438万股，总成交金额港币$8.104千万。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT24050370/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2432641602","title":"信达生物午盘涨超9% 一季度总产品收入增超60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2432641602","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2432641602?lang=zh_cn&edition=full","pubTime":"2024-05-02 15:14","pubTimestamp":1714634049,"startTime":"0","endTime":"0","summary":"信达生物（01801）午盘上涨9.54%，现报41.90港元，成交额2.72亿港元。\n　　信达生物发布公告，2024年第一季度，公司共取得总产品收入超过人民币17亿元，同比取得超60%的强劲增长。于季度内，得益于广阔的适应症潜力、医保覆盖和完备的准入渠道等优势，整体产品组合持续保持快速增长态势。达伯舒（信迪利单抗注射液）持续取得强劲的销售表现和稳固的市场领先地位，其他产品亦增长显著，尤其新产品加速成长，贡献不断提升。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-05-02/doc-inatvmfc7520699.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-05-02/doc-inatvmfc7520699.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2432864917","title":"港股异动 | 信达生物(01801)现涨超9% 一季度总产品收入增超60% 公司将在ASCO公布多项临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2432864917","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2432864917?lang=zh_cn&edition=full","pubTime":"2024-05-02 14:59","pubTimestamp":1714633148,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，信达生物现涨超9%，截至发稿，涨9.02%，报41.7港元，成交额2.65亿港元。消息面上，信达生物发布公告，2024年第一季度，公司共取得总产品收入超过人民币17亿元，同比取得超60%的强劲增长。此外，信达生物宣布，将在2024年美国临床肿瘤学会年会上公布约20项最新临床研究数据，包括公司旗下一系列单抗、双抗及抗体偶联药物在研管线，及达伯舒、耐立克、他雷替尼等创新肿瘤药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1116872.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432820613","title":"信达生物(01801)上涨5.1%，报40.2元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2432820613","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2432820613?lang=zh_cn&edition=full","pubTime":"2024-05-02 11:47","pubTimestamp":1714621679,"startTime":"0","endTime":"0","summary":"5月2日，信达生物(01801)盘中上涨5.1%，截至11:47，报40.2元/股，成交1.12亿元。信达生物制药主营业务是开发、生产和销售肿瘤、自身免疫、代谢、眼科等重大疾病领域的创新药物，已成功建立起了包括35个新药品种的产品链，并获得9个产品的批准上市。至2023年3月，信达生物的患者援助项目已惠及16余万普通患者，药物捐赠总价值数亿元，与礼来、罗氏、赛诺菲等公司达成了30项战略合作。截至2023年年报，信达生物营业总收入62.06亿元、净利润-10.28亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/02114740509374.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2432618039","title":"信达生物盘中异动 临近午盘急速上涨5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2432618039","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432618039?lang=zh_cn&edition=full","pubTime":"2024-05-02 11:47","pubTimestamp":1714621671,"startTime":"0","endTime":"0","summary":"2024年05月02日临近午盘11时47分，信达生物股票出现波动，股价大幅拉升5.10%。截至发稿，该股报40.201港元/股，成交量284.208万股，换手率0.18%，振幅7.06%。信达生物股票所在的药品行业中，整体涨幅为0.48%。该公司的产品还包括阿达木单抗生物类似药IBI-303,用于治疗类风湿性关节炎、强直性脊柱炎及银屑病。利妥昔单抗生物类似药IBI-301,用于治疗非霍奇金淋巴瘤及慢性淋巴细胞白血病。消息层面，截至11时47分，信达生物股票正面舆情新闻比例25%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050211475187e854b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050211475187e854b4&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431323594","title":"新人｜信达生物新任命首席商务官","url":"https://stock-news.laohu8.com/highlight/detail?id=2431323594","media":"健识局","top":-1,"share":"https://www.laohu8.com/m/news/2431323594?lang=zh_cn&edition=full","pubTime":"2024-04-30 21:17","pubTimestamp":1714483040,"startTime":"0","endTime":"0","summary":"4月30日，信达生物宣布，任命张苏华为全球首席商务官，负责公司在全球业务的战略规划和商务拓展工作。2022年7月，张苏华加入亘喜生物。去年年底，阿斯利康宣布收购亘喜生物，并于今年2月收购完成，亘喜生物正式成为阿斯利康的全资子公司。收购完成后，张苏华功成身退，去到了信达生物。在加入亘喜生物之前，张苏华曾任NeoImmuneTech公司首席商务官，并在礼来、辉瑞、百时美施贵宝、诺华以及Merus公司担任过各类管理岗位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043021190087c3e8e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043021190087c3e8e1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431399775","title":"信达生物(01801.HK)首季总产品收入按年增逾60%至逾17亿人币","url":"https://stock-news.laohu8.com/highlight/detail?id=2431399775","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2431399775?lang=zh_cn&edition=full","pubTime":"2024-04-30 17:04","pubTimestamp":1714467840,"startTime":"0","endTime":"0","summary":"信达生物(01801.HK) 公布，首季共取得总产品收入超过17亿元人民币，按年增长超过60%。目前公司已取得10款产品获批上市，3个品种的新药上市申请(NDA)在国家药品监督管理局(NMPA)审评中，5个新药分子进入III期或关键性临床研究，另外还有18个新药品种已进入临床研究。(ha/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-30 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190319114710011_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190319114710011_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1346525/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2431396963","title":"信达生物(01801.HK)：一季度取得总产品收入超过17亿元 同比强劲增长超60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431396963","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2431396963?lang=zh_cn&edition=full","pubTime":"2024-04-30 17:03","pubTimestamp":1714467834,"startTime":"0","endTime":"0","summary":"格隆汇4月30日丨信达生物(01801.HK)发布公告，2024年第一季度，公司共取得总产品收入超过人民币17亿元，同比取得超60%的强劲增长。于季度内，得益于广阔的适应症潜力、医保覆盖和完备的准入渠道等优势，整体产品组合持续保持快速增长态势。达伯舒®(信迪利单抗注射液)持续取得强劲的销售表现和稳固的市场领先地位，其他产品亦增长显著，尤其新产品加速成长，贡献不断提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043017040087c31a0f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043017040087c31a0f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431368562","title":"信达生物(01801)出现大手成交14.55万股，成交价$38.2，涉资555.81万","url":"https://stock-news.laohu8.com/highlight/detail?id=2431368562","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2431368562?lang=zh_cn&edition=full","pubTime":"2024-04-30 14:48","pubTimestamp":1714459680,"startTime":"0","endTime":"0","summary":"[大手成交]信达生物(01801)在下午02:48出现大手成交，成交量为14.55万，成交价为港币$38.2，涉资555.81万。至目前为止，股价跌3.774%，今日最高价为$40.4，而最低价为$38.0，总成交量为658.349万股，总成交金额港币$2.554亿。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180126132515779_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180126132515779_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2404303222/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2431324333","title":"信达生物任命张苏华为全球首席商务官","url":"https://stock-news.laohu8.com/highlight/detail?id=2431324333","media":"界面","top":-1,"share":"https://www.laohu8.com/m/news/2431324333?lang=zh_cn&edition=full","pubTime":"2024-04-30 12:53","pubTimestamp":1714452828,"startTime":"0","endTime":"0","summary":"4月30日，信达生物制药宣布任命张苏华（Samuel Zhang）为全球首席商务官（CBO）。张苏华将负责信达生物在全球业务的战略规划和商务拓展工作，向公司创始人、董事长兼首席执行官俞德超汇报。张苏华在加入信达生物之前曾担任亘喜生物和NeoImmune Tech公司首席商务官，主导了亘喜生物与阿斯利康价值12亿美元的收购合作。他还曾在礼来、辉瑞、百时美施贵宝、诺华以及Merus公司担任过各类管理岗位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301253487a579a20&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301253487a579a20&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431450334","title":"信达生物宣布任命张苏华博士为全球首席商务官","url":"https://stock-news.laohu8.com/highlight/detail?id=2431450334","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2431450334?lang=zh_cn&edition=full","pubTime":"2024-04-30 12:30","pubTimestamp":1714451400,"startTime":"0","endTime":"0","summary":"美国旧金山和中国苏州2024年4月30日 /美通社/ -- 信达生物制药，一家致力于研发、生产和销售肿瘤、自身免疫、代谢及心血管、眼科等重大疾病领域创新药物的生物制药公司，今日宣布，任命张苏华博士为全球首席商务官。信达生物创始人、董事长兼首席执行官俞德超博士表示：\"非常高兴张苏华博士加入信达生物并担任首席商务官，张博士在商务拓展领域拥有丰富的经验以及卓越的领导能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4401027_ZH01027_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2431392002","title":"信达生物(01801)上涨2.04%，报39.95元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2431392002","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2431392002?lang=zh_cn&edition=full","pubTime":"2024-04-29 15:59","pubTimestamp":1714377570,"startTime":"0","endTime":"0","summary":"4月29日，信达生物(01801)盘中上涨2.04%，截至15:59，报39.95元/股，成交3.39亿元。信达生物制药主营业务是开发、生产和销售肿瘤、自身免疫、代谢、眼科等重大疾病领域的创新药物，已成功建立起了包括35个新药品种的产品链，并获得9个产品的批准上市。至2023年3月，信达生物的患者援助项目已惠及16余万普通患者，药物捐赠总价值数亿元，与礼来、罗氏、赛诺菲等公司达成了30项战略合作。截至2023年年报，信达生物营业总收入62.06亿元、净利润-10.28亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/29155940466611.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430589417","title":"信达生物将在美国临床肿瘤学会（ASCO）2024年大会公布多项临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2430589417","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2430589417?lang=zh_cn&edition=full","pubTime":"2024-04-25 09:50","pubTimestamp":1714009800,"startTime":"0","endTime":"0","summary":"美国旧金山和中国苏州2024年4月25日 /美通社/ -- 信达生物制药集团，一家致力于研发、生产和销售肿瘤、自身免疫、代谢及心血管、眼科等重大疾病领域创新药物的生物制药公司，今日宣布，将在 2024 年美国临床肿瘤学会年会上公布约20项最新临床研究数据，包括公司旗下一系列单抗、双抗及抗体偶联药物在研管线，及达伯舒、耐立克、他雷替尼等创新肿瘤药物。本届 ASCO 年会将于当地时间2024年5月31日-6月4日在美国芝加哥举办。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4396236_ZH96236_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2429483717","title":"信达生物现涨超6% 机构预计减肥药的上市数量将大幅增加","url":"https://stock-news.laohu8.com/highlight/detail?id=2429483717","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2429483717?lang=zh_cn&edition=full","pubTime":"2024-04-24 15:35","pubTimestamp":1713944147,"startTime":"0","endTime":"0","summary":"信达生物（01801）尾盘上涨6.36%，现报38.45港元，成交额3.12亿港元。\n　　Global Data发布报告称，由于对减肥产品的需求激增，制药商正准备在未来五年内在美国推出约13种新的减肥疗法。该机构表示，预计减肥药的上市数量将大幅增加，2027年和2028年将达到每年四款的峰值。相比之下，2019年至2023年间仅推出了三款产品。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-24/doc-inasxkky8588367.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-24/doc-inasxkky8588367.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":0.0447},{"period":"1month","weight":0.1314},{"period":"3month","weight":0.2801},{"period":"6month","weight":-0.1147},{"period":"1year","weight":0.0474},{"period":"ytd","weight":-0.0433}],"compareEarnings":[{"period":"1week","weight":0.0467},{"period":"1month","weight":0.1047},{"period":"3month","weight":0.1894},{"period":"6month","weight":0.046},{"period":"1year","weight":-0.0738},{"period":"ytd","weight":0.0838}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"信达生物制药是一家主要从事生物制药的投资控股公司。该公司及其子公司从事抗体及蛋白质医药产品的研发、药品的销售及分销，以及提供咨询及研发服务。该公司的主要产品为达伯舒（信迪利单抗注射液），用于治疗复发或难治性经典霍奇金淋巴瘤。该公司的产品还包括阿达木单抗生物类似药IBI-303，用于治疗类风湿性关节炎、强直性脊柱炎及银屑病。贝伐珠单抗生物类似药IBI-305，用于治疗转移性结直肠癌及晚期、转移性或复发性非小细胞肺癌（NSCLC）。利妥昔单抗生物类似药IBI-301，用于治疗非霍奇金淋巴瘤及慢性淋巴细胞白血病。该公司的产品应用于肿瘤、代谢、免疫学及眼底病等领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.049204},{"month":2,"riseRate":0.666667,"avgChangeRate":0.101831},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.050735},{"month":4,"riseRate":0.666667,"avgChangeRate":0.022046},{"month":5,"riseRate":0.5,"avgChangeRate":0.031374},{"month":6,"riseRate":0.6,"avgChangeRate":0.132633},{"month":7,"riseRate":0.2,"avgChangeRate":-0.046248},{"month":8,"riseRate":0.8,"avgChangeRate":-0.016733},{"month":9,"riseRate":0.6,"avgChangeRate":0.024076},{"month":10,"riseRate":0.4,"avgChangeRate":0.043974},{"month":11,"riseRate":0.5,"avgChangeRate":0.068539},{"month":12,"riseRate":0.5,"avgChangeRate":0.07208}],"exchange":"SEHK","name":"信达生物","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信达生物,01801,信达生物股票,信达生物股票老虎,信达生物股票老虎国际,信达生物行情,信达生物股票行情,信达生物股价,信达生物股市,信达生物股票价格,信达生物股票交易,信达生物股票购买,信达生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}